维吾尔族妇女宫颈癌患者的免疫状态及其与临床病理因素的关系

doi:10.3969/j.issn.1004-616x.2016.05.007

癌变·畸变·突变 ›› 2016, Vol. 28 ›› Issue (5): 369-371,376.doi: 10.3969/j.issn.1004-616x.2016.05.007

维吾尔族妇女宫颈癌患者的免疫状态及其与临床病理因素的关系

盛磊¹, 茹明芳², 武贵臻¹, 杨云³, 阿布力孜·阿布杜拉¹

1. 新疆医科大学新疆地方病分子生物学重点实验室, 新疆乌鲁木齐 830011;
2. 新疆医科大学附属肿瘤医院心肺功能科, 新疆乌鲁木齐 830011;
3. 新疆医科大学基础医学院生物化学与分子生物学教研室, 新疆乌鲁木齐 830011

收稿日期:2016-04-18 修回日期:2016-05-31 出版日期:2016-09-30 发布日期:2016-09-30
通讯作者: 阿布力孜·阿布杜拉,E-mail:abulizi_de@126.com E-mail:abulizi_de@126.com
作者简介:盛磊,E-mail:shenglei950505@163.com
基金资助:
新疆维吾尔自治区自然科学基金项目（2014211C023）

Association between immune state and clinical pathologic parameters in cervical cancer of Uighur women

SHENG Lei¹, RU Mingfang², WU Guizhen¹, YANG Yun³, ABUDULA·Abulizi¹

1. Xinjiang Key Laboratory of Molecular Biology and Endemic Diseases, Xinjiang Medical University, Urumqi 830011;
2. Department of Cardio-pulmonary Function, Affiliated Tumor Hospital of Xinjiang Medical University, Urumqi 830011;
3. Department of Biochemistry, College of Basic Medicine, Xinjiang Medical University, Urumqi 830011, Xinjiang, China

Received:2016-04-18 Revised:2016-05-31 Online:2016-09-30 Published:2016-09-30

摘要/Abstract

摘要： 目的：利用新疆特有的病例资源，评估维吾尔族妇女宫颈癌患者的免疫水平，探讨宫颈癌患者血浆中白细胞介素（IL-2和IL-10）的表达水平及其与临床病理因素之间的关系。方法：收集宫颈癌50例、癌前病变（CIN Ⅲ）患者20例及对照组（正常或慢性宫颈炎患者）18例的外周血标本，使用酶联免疫吸附实验（ELISA）法检测血浆中细胞因子IL-2和IL-10的表达水平。结果：与对照组相比较，宫颈癌和癌前病变组IL-2的表达水平显著降低（P<0.05），IL-10的表达水平显著升高（P<0.05）；在宫颈癌组中，IL-10的表达水平随肿瘤分期逐渐升高（P<0.05）；对照组中汉族与维吾尔族人群血浆中IL-2表达水平无显著差异（P>0.05），宫颈癌组中维吾尔族患者血浆IL-2表达水平较汉族患者显著降低（P<0.05）。结论：宫颈癌患者细胞免疫水平低下，体内发生免疫抑制，提示这可能是宫颈癌细胞发生免疫逃逸的机制之一，IL-2可能在维吾尔族宫颈癌发生发展过程中起到重要作用。

关键词: 宫颈癌, 白细胞介素-2, 白细胞介素-10, 酶联免疫吸附实验, 免疫水平

Abstract: OBJECTIVE: The aim of this study was to investigate the association between IL-2 and IL-10 cytokine levels in plasma,and clinical pathologic factors in cervical cancer of Uighur women. METHODS: Peripheral blood specimens from 50 cervical cancer patients,20 patients with CIN Ⅲ precancerous lesions and 18 controls were used to detect IL-2 and IL-10 by ELISA. RESULTS: The results show that expressions of IL-2 in plasma from patients with cervical cancer or precancerous lesions was significantly reduced compared with those from the controls (P<0.05),while expressions of IL-10 was significantly increased (P<0.05). From the cervical cancer group,IL-10 expression was gradually increased with tumor pathological staging (P<0.05),while IL-2 expression level did not show obvious relationship with tumor pathological staging (P>0.05). Moreover,there was no significant difference in IL-2 expression (P>0.05) between normal Han and Uighur populations,but among those with cervical cancer,Uighur patients' IL-2 expression level was significantly lower than that in Han patients (P<0.05). CONCLUSION: Our results show that immunosuppression occurred despite having low cellular immune level among cervical cancer patients. The observation suggests that one of the mechanisms may be immune escape of tumor cells. In addition,IL-2 may have played an important role in cervical carcinogenesis among Uighur women.

Key words: cervical cancer, IL-2, IL-10, enzyme linked immunosorbent assay, immune level

中图分类号:

R737.33

盛磊, 茹明芳, 武贵臻, 杨云, 阿布力孜·阿布杜拉. 维吾尔族妇女宫颈癌患者的免疫状态及其与临床病理因素的关系[J]. 癌变·畸变·突变, 2016, 28(5): 369-371,376.

SHENG Lei, RU Mingfang, WU Guizhen, YANG Yun, ABUDULA·Abulizi. Association between immune state and clinical pathologic parameters in cervical cancer of Uighur women[J]. Carcinogenesis, Teratogenesis & Mutagenesis, 2016, 28(5): 369-371,376.

参考文献

[1] 李莹.免疫系统在癌症治疗中的两面性[J].现代预防医学,2006,33(9):1565-1567.
[2] 李国玲,林华笙,韩雪飞,等.恶性肿瘤患者的免疫学变化[J].中华临床新医学,2004,4(1):9-10.
[3] de Visser KE,Coussens LM.The interplay between innate and adaptive immunity regulates cancer development[J].Cancer Immunol Immunother,2005,54(11):1143-4452.
[4] Malmberg KJ.Effective immunotherapy against cancer:a question of overcoming immune suppression and immune escape[J].Cancer Immunol Immunother,2004,53:879-892.
[5] Mamessier E,Sylvain A,Bertucci F,et al.Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition[J].Cancer Res,2011,71(21):6621-6632.
[6] Ito N,Nakamura H,Metsugi H,et al.Dissociation between T helper type 1 and type 2 differentiation and cytokine production in tumor-infiltrating lymphocytes in patients with lung cancer[J].Surg Today,2001,31(5):390-394.
[7] Mahajan R,El-Omar EM,Lissowska J,et al.Genetic variants in T helper cell type 1,2 and 3 pathways and gastric cancer risk in a Polish population[J].Jpn J Clin Oncol,2008,38(9):626-633.
[8] Sun Y,Qian C,Peng D,et al.Gene transfer to liver cancer cells of B7-1 plus interleukin 12 changes immunoeffector mechanisms and suppresses helper T cell type 1 cytokine production induced by interleukin 12 alone[J].Hum Gene Ther,2000,11(1):127-138.
[9] De Monte L,Reni M,Tassi E,et al.Intratumor T helper type 2 cell infiltrate correlates with cancer-associated fibroblast thymic stromal lymphopoietin production and reduced survival in pancreatic cancer[J].J Exp Med,2011,208(3):469-478.
[10] Ehi K,Ishigami S,Masamoto I,et al.Analysis of T-helper type 1 and 2 cells and T-cytotoxic type 1 and 2 cells of sentinel lymph nodes in breast cancer[J].Oncol Rep,2008,19(3):601-607.
[11] 盛磊,阿仙姑·哈斯木,刘开江,等.维吾尔族妇女宫颈病变病理进程与降钙素相关肽α表达的关系[J].癌变·畸变·突变,2011,23(4):287-290.
[12] Miyazaki T,Liu ZJ,Kawahara A,et al.Three distinct IL-2 signaling pathways mediated by bcl-2,c-myc,and lck cooperate in hematopoietic cell proliferation[J].Cell,1995,81(2):223-231.
[13] Shevach EM.Application of IL-2 therapy to target T regulatory cell function[J].Trends Immunol,2012,33(12):626-632.
[14] Lan RY,Selmi C,Gershwin ME.The regulatory,inflammatory,and T cell programming roles of interleukin-2(IL-2)[J].J Autoimmun,2008,31(1):7-12.
[15] Gruenbacher G,Gander H,Nussbaumer O,et al.IL-2 costimulation enables statin-mediated activation of human NK cells,preferentially through a mechanism involving CD56⁺ dendritic cells[J].Cancer Res,2010,70(23):9611-9620.
[16] Kim MT,Richer MJ,Gross BP,et al.Enhancing dendritic cell-based immunotherapy with IL-2/monoclonal antibody complexes for control of established tumors[J].Immunol,2015,195(9):4537-4544.
[17] Kang TH,Mao CP,He L,et al.Tumor-targeted delivery of IL-2 by NKG2D leads to accumulation of antigen-specific CD8+T cells in the tumor loci and enhanced anti-tumor effects[J].PLoS One,2012,7(4):e35141.
[18] Geginat J,Larghi P,Paroni M,et al.The light and the dark sides of Interleukin-10 in immune-mediated diseases and cancer[J/OL].Cytokine Growth Factor Rev,2016.doi:10.1016/j.cytogfr.2016.02.003.
[19] Ma X,Yan W,Zheng H,et al.Regulation of IL-10 and IL-12 production and function in macrophages and dendritic cells[J/OL].F1000 Res,2015.doi:10.12688/f1000 research.7010.1.
[20] Couper KN,Blount DG,Riley EM.IL-10:the master regulator of immunity to infection[J].J Immunol,2008,180(9):5771-5777.
[21] Trifunović 1,Miller L,DebeljakŽ,et al.Pathologic patterns of interleukin 10 expression-a review[J].Biochem Med (Zagreb),2015,25(1):36-48.

维吾尔族妇女宫颈癌患者的免疫状态及其与临床病理因素的关系

Association between immune state and clinical pathologic parameters in cervical cancer of Uighur women

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	王晓舟, 李洪石, 于溪, 魏宁, 王梓瑛, 赫丽杰. 青藤碱对HPV阳性宫颈癌SiHa细胞增殖和侵袭的影响[J]. 癌变·畸变·突变, 2021, 33(6): 442-445.
[2]	方磊, 杨涛, 盛磊, 木塔力甫·艾买提, 齐鑫鑫, 艾尼娃尔·艾克木, 伊力亚尔·尼加提. 黑种草子总皂苷对人宫颈癌SiHa细胞生物学行为的影响[J]. 癌变·畸变·突变, 2021, 33(2): 143-148,152.
[3]	兰莉, 陈海丽, 徐蕾. RBMS3-AS3对宫颈癌细胞增殖、凋亡和侵袭的影响及作用机制[J]. 癌变·畸变·突变, 2020, 32(6): 438-443.
[4]	王媛媛, 陈依超, 郑洁, 彭燕燕, 王少洪. 汕头市妇女HPV-52感染与宫颈鳞状上皮病变的关系[J]. 癌变·畸变·突变, 2020, 32(4): 304-308.
[5]	盛磊, 武贵臻, 热娜古丽·热依木, 艾尼娃尔·艾克木. 新疆黑种草子总黄酮体外抗宫颈癌活性研究[J]. 癌变·畸变·突变, 2019, 31(5): 385-391.
[6]	徐苗, 张天一, 田菲菲. PD-1/PD-L1信号通路抑制剂在宫颈癌治疗中的研究进展[J]. 癌变·畸变·突变, 2019, 31(5): 417-420.
[7]	郝轶, 袁建林, 肖悦, 李卉, 郭霞. 3种不同的HPV型别宫颈癌细胞株分泌蛋白非标记定量技术分析[J]. 癌变·畸变·突变, 2018, 30(5): 354-358,364.
[8]	迪拉热·力迪甫, 木塔力甫·艾买提, 盛磊, 古扎力努尔买提沙, 艾尔肯·肉孜比拉力, ABULIZI Abudula. HPV16编码蛋白与宫颈癌细胞内CALCA和TFPI-2表达的关系[J]. 癌变·畸变·突变, 2017, 29(6): 431-436.
[9]	宋淑芳, 常海平, 杨彩容, 赵荣伟, 张龙, 任杰, 郑健. 慢病毒介导的TPX2基因沉默对人宫颈癌HeLa细胞系增殖、迁移和细胞周期的影响及机制[J]. 癌变·畸变·突变, 2017, 29(5): 329-334,339.
[10]	刘好, 赵滢滢, 金平, 许改霞, 郭宇然, 张可, 王晓梅, 张蕾. 组蛋白去乙酰化酶抑制剂联合紫杉醇抑制宫颈癌细胞增殖的体外实验[J]. 癌变·畸变·突变, 2017, 29(5): 335-339.
[11]	丁立新, 赵现哲, 姜晓燕, 丁库克. 宫颈癌辐射敏感性相关基因的研究进展[J]. 癌变·畸变·突变, 2017, 29(5): 394-396,401.
[12]	沈伶, 许丽璇, 李小平, 胡桂英, 麦碧, 纪璇, 粟丽. 粤东地区妇女人乳头瘤病毒感染情况和亚型分布及其与宫颈癌的关系[J]. 癌变·畸变·突变, 2017, 29(3): 226-229.
[13]	刘平. 长链非编码RNA XIST和miR-101-3p在子宫颈癌组织中的表达及关系[J]. 癌变·畸变·突变, 2017, 29(2): 121-124.
[14]	张雪杉, 缪芳, 曹晏宁, 张晓姝. 婆罗双树样基因2干扰对宫颈癌HeLa细胞增殖和凋亡的影响[J]. 癌变·畸变·突变, 2016, 28(5): 359-363,368.
[15]	栗丽, 胡桂英, 吴宇丹, 沈伶. 薄层液基细胞学联合HPV-DNA检测在粤东地区宫颈癌筛查中的临床价值[J]. 癌变·畸变·突变, 2016, 28(4): 281-283,291.